DE69422450D1 - Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose - Google Patents
Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von OsteoporoseInfo
- Publication number
- DE69422450D1 DE69422450D1 DE69422450T DE69422450T DE69422450D1 DE 69422450 D1 DE69422450 D1 DE 69422450D1 DE 69422450 T DE69422450 T DE 69422450T DE 69422450 T DE69422450 T DE 69422450T DE 69422450 D1 DE69422450 D1 DE 69422450D1
- Authority
- DE
- Germany
- Prior art keywords
- osteoporosis
- quinolines
- medicament
- manufacture
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15865293 | 1993-06-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69422450D1 true DE69422450D1 (de) | 2000-02-10 |
DE69422450T2 DE69422450T2 (de) | 2000-06-08 |
Family
ID=15676394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69422450T Expired - Fee Related DE69422450T2 (de) | 1993-06-29 | 1994-06-25 | Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose |
Country Status (5)
Country | Link |
---|---|
US (2) | US5719157A (de) |
EP (1) | EP0634169B1 (de) |
AT (1) | ATE188377T1 (de) |
CA (1) | CA2126966A1 (de) |
DE (1) | DE69422450T2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0749426A1 (de) * | 1994-03-08 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Chinolin- oder chinazolinderivate als entzündunshemmende mitteln, insbesondere zur behandlung von arthritis |
US5641788A (en) | 1994-06-07 | 1997-06-24 | Takeda Chemical Industries, Ltd. | Quinoline derivatives and pharmaceutical composition containing them |
AU5348396A (en) * | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
ATE206701T1 (de) * | 1996-04-19 | 2001-10-15 | American Home Prod | Östrogene verbindungen |
ID18046A (id) * | 1996-08-20 | 1998-02-19 | Takeda Chemical Industries Ltd | Senyawa siklik campuran, pembuatan dan penngunaannya. |
US6251901B1 (en) * | 1996-10-23 | 2001-06-26 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
US6262269B1 (en) | 1997-02-04 | 2001-07-17 | Trega Biosciences, Inc. | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries |
AU8191998A (en) * | 1997-02-04 | 1998-08-25 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
US6340704B1 (en) | 1997-04-25 | 2002-01-22 | Takeda Chemical Industries, Ltd. | Cell differentiation inducing amide derivatives, their production and use |
JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス,インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6787082B1 (en) * | 1999-01-29 | 2004-09-07 | Takeda Chemical Industries, Ltd. | Compressing mallet with coating treatment |
US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
FR2801310B1 (fr) * | 1999-11-24 | 2004-04-16 | Adir | NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
CN1234691C (zh) * | 2001-03-02 | 2006-01-04 | 住友化学工业株式会社 | 喹啉-3-羧酸化合物的制备方法 |
AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
US7232824B2 (en) * | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
WO2009023631A1 (en) * | 2007-08-10 | 2009-02-19 | Basil Rigas | Anti-inflammatory compounds and uses thereof |
MX2011010523A (es) * | 2009-04-06 | 2011-10-28 | Daiichi Sankyo Co Ltd | Compuesto ciclico que tiene grupo fenilo sustituido. |
MX351368B (es) | 2010-05-26 | 2017-10-12 | Sunovion Pharmaceuticals Inc | Compuestos heteroarilo y metodos para utilizarlos. |
EP2609084A1 (de) | 2010-08-27 | 2013-07-03 | Grünenthal GmbH | Substituierte 2-aminochinolin-3-carboxamide als kcnq-2/3-modulatoren |
AU2011295408B2 (en) | 2010-08-27 | 2015-05-14 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators |
PT2609083E (pt) | 2010-08-27 | 2015-07-01 | Gruenenthal Gmbh | 2-oxi-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 |
BR112013004721A2 (pt) * | 2010-08-27 | 2016-05-17 | Gruenenthal Gmbh | "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3" |
JP5976649B2 (ja) | 2010-09-01 | 2016-08-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Kcnq2/3調節因子としての置換1−オキソ−ジヒドロイソキノリン−3−カルボキサミド |
WO2014029723A1 (en) * | 2012-08-24 | 2014-02-27 | F. Hoffmann-La Roche Ag | New bicyclicpyridine derivatives |
US11731980B1 (en) | 2023-03-22 | 2023-08-22 | King Faisal University | Furo[3,4-b]quinolone compounds as antibacterial agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3800039A (en) * | 1970-10-21 | 1974-03-26 | Mead Johnson & Co | Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines |
FR2134169A1 (en) * | 1971-04-23 | 1972-12-08 | Clin Byla Ets | 3-acyl-4-substd - quinoline derivs - analgesics, antiinflammatories, diuretics |
JPS53141286A (en) * | 1977-05-16 | 1978-12-08 | Kyorin Seiyaku Kk | Novel substituted quinolinecarboxylic acid |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
JPH0692410B2 (ja) * | 1988-08-30 | 1994-11-16 | キッセイ薬品工業株式会社 | 新規なベンゾフロキノリン誘導体 |
GB8910722D0 (en) * | 1989-05-10 | 1989-06-28 | Smithkline Beckman Intercredit | Compounds |
PT94305B (pt) * | 1989-06-12 | 1997-02-28 | Robins Co Inc A H | Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos |
US5124325A (en) * | 1989-06-13 | 1992-06-23 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agents of metabolic bone disease |
US5352684A (en) * | 1990-04-10 | 1994-10-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridines as medicaments |
US5126351A (en) * | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
DE4105551A1 (de) * | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
DE4129742A1 (de) * | 1991-09-06 | 1993-03-11 | Bayer Ag | Heterocyclisch substituierte chinolylmethoxy-phenylacetamide |
TW232013B (de) * | 1992-04-24 | 1994-10-11 | Takeda Pharm Industry Co Ltd | |
NO179904C (no) * | 1992-09-04 | 1997-01-08 | Takeda Chemical Industries Ltd | Kondenserte heterocykliske forbindelser og deres anvendelse |
NO940245D0 (no) * | 1993-01-28 | 1994-01-24 | Takeda Chemical Industries Ltd | Quinolin eller quinazolinderivater, deres fremstilling og anvendelse |
-
1994
- 1994-06-25 EP EP94109861A patent/EP0634169B1/de not_active Expired - Lifetime
- 1994-06-25 AT AT94109861T patent/ATE188377T1/de active
- 1994-06-25 DE DE69422450T patent/DE69422450T2/de not_active Expired - Fee Related
- 1994-06-28 CA CA002126966A patent/CA2126966A1/en not_active Abandoned
-
1996
- 1996-11-25 US US08/756,189 patent/US5719157A/en not_active Expired - Fee Related
-
1997
- 1997-01-15 US US08/783,079 patent/US5852039A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69422450T2 (de) | 2000-06-08 |
EP0634169A1 (de) | 1995-01-18 |
EP0634169B1 (de) | 2000-01-05 |
ATE188377T1 (de) | 2000-01-15 |
US5719157A (en) | 1998-02-17 |
CA2126966A1 (en) | 1994-12-30 |
US5852039A (en) | 1998-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69422450D1 (de) | Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose | |
DE60042172D1 (de) | Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen | |
DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
DE69034148D1 (de) | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie | |
DE69940199D1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
DE69428130D1 (de) | Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten | |
ATE271385T1 (de) | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
DE69122099D1 (de) | Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
DE59405376D1 (de) | Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten | |
ATE198706T1 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
DE69501419D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose enthaltend Xanthohumol | |
ATE336997T1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
DE69429806D1 (de) | Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung | |
DE60218843D1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
ATE266027T1 (de) | Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE148109T1 (de) | Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |